Investigating the Efficacy and Safety of the CyberKnife System for Treating Primary Pancreatic Cancer with Metastases to the Gastrointestinal Tract.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
106 patients with primary pancreatic cancer and metastases to the gastrointestinal tract admitted to our hospital received CyberKnife treatment.
I · Intervention 중재 / 시술
CyberKnife treatment
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Quality of life improved in 27 patients, remained stable in 52, and declined in 27, yielding an overall improvement or stabilization rate of 74.53% (79 cases). [CONCLUSION] CyberKnife SBRT appears to be a promising treatment modality for managing primary pancreatic cancer with metastases to the gastrointestinal tract, with minimal adverse reactions.
[OBJECTIVE] This study aimed to investigate the effectiveness and safety of CyberKnife in the treatment of primary pancreatic cancer with metastases to the gastrointestinal tract (ie, primary pancreat
- p-value p<0.001
APA
Zhang Z, Tian B, et al. (2025). Investigating the Efficacy and Safety of the CyberKnife System for Treating Primary Pancreatic Cancer with Metastases to the Gastrointestinal Tract.. Cancer management and research, 17, 1589-1598. https://doi.org/10.2147/CMAR.S526924
MLA
Zhang Z, et al.. "Investigating the Efficacy and Safety of the CyberKnife System for Treating Primary Pancreatic Cancer with Metastases to the Gastrointestinal Tract.." Cancer management and research, vol. 17, 2025, pp. 1589-1598.
PMID
40791647 ↗
Abstract 한글 요약
[OBJECTIVE] This study aimed to investigate the effectiveness and safety of CyberKnife in the treatment of primary pancreatic cancer with metastases to the gastrointestinal tract (ie, primary pancreatic adenocarcinoma metastasizing to gastrointestinal organs).
[METHODS] A total of 106 patients with primary pancreatic cancer and metastases to the gastrointestinal tract admitted to our hospital received CyberKnife treatment. Recent treatment efficacy (assessed at 3 months post-treatment), median survival period, pain levels, and adverse reactions were analyzed.
[RESULTS] Among the 106 patients, 17 cases (16.04%) achieved complete response (CR), 61 cases (57.55%) achieved partial response (PR), 20 cases (18.87%) had stable disease (SD), and 8 cases (7.55%) had progressive disease (PD), resulting in an objective response rate (ORR) of 73.59% and an overall disease control rate (DCR) of 92.45% (98 cases). The one-year and two-year overall survival (OS) rates were 74.53% and 55.66%, respectively, while the local control (LC) rates were 92.45% and 87.74%, respectively. The median OS was 8.17 months (range: 1-25 months). Mean pain scores (Visual Analog Scale) decreased significantly from 5.38±1.37 at baseline to 2.01±0.35 post-treatment (p<0.001). Abdominal and lumbar pain significantly improved after 2 weeks of radiotherapy. Among the 68 patients with baseline pain who experienced relief, analgesic medication was discontinued in 25 (36.8%) patients, reduced by ≥50% in 18 patients (26.5%), and by approximately 25% in 5 patients (7.3%). Quality of life improved in 27 patients, remained stable in 52, and declined in 27, yielding an overall improvement or stabilization rate of 74.53% (79 cases).
[CONCLUSION] CyberKnife SBRT appears to be a promising treatment modality for managing primary pancreatic cancer with metastases to the gastrointestinal tract, with minimal adverse reactions.
[METHODS] A total of 106 patients with primary pancreatic cancer and metastases to the gastrointestinal tract admitted to our hospital received CyberKnife treatment. Recent treatment efficacy (assessed at 3 months post-treatment), median survival period, pain levels, and adverse reactions were analyzed.
[RESULTS] Among the 106 patients, 17 cases (16.04%) achieved complete response (CR), 61 cases (57.55%) achieved partial response (PR), 20 cases (18.87%) had stable disease (SD), and 8 cases (7.55%) had progressive disease (PD), resulting in an objective response rate (ORR) of 73.59% and an overall disease control rate (DCR) of 92.45% (98 cases). The one-year and two-year overall survival (OS) rates were 74.53% and 55.66%, respectively, while the local control (LC) rates were 92.45% and 87.74%, respectively. The median OS was 8.17 months (range: 1-25 months). Mean pain scores (Visual Analog Scale) decreased significantly from 5.38±1.37 at baseline to 2.01±0.35 post-treatment (p<0.001). Abdominal and lumbar pain significantly improved after 2 weeks of radiotherapy. Among the 68 patients with baseline pain who experienced relief, analgesic medication was discontinued in 25 (36.8%) patients, reduced by ≥50% in 18 patients (26.5%), and by approximately 25% in 5 patients (7.3%). Quality of life improved in 27 patients, remained stable in 52, and declined in 27, yielding an overall improvement or stabilization rate of 74.53% (79 cases).
[CONCLUSION] CyberKnife SBRT appears to be a promising treatment modality for managing primary pancreatic cancer with metastases to the gastrointestinal tract, with minimal adverse reactions.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Modified Use of Costal Cartilage in Asians for the Correction of Nostril Asymmetry in Unilateral Secondary Cleft Lip Nasal Deformity.
- Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy.
- Comparison of oncological outcomes between wedge resection and segmentectomy for T1a/bN0M0 non-small-cell lung cancer: a population-based retrospective cohort study.
- Tumor-derived C4BPA promotes macrophage M2-like polarization through C5a -C5aR1-STAT3 axis and drives gastric cancer progression.
- Innate immunity in tumour immunoediting and immunosurveillance.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Key Considerations for Targeting in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.
- The role of disulfidptosis-driven tumor microenvironment remodeling in pancreatic cancer progression.
- Current Systemic Treatment Options for Advanced Pancreatic Cancer-An Overview Article.
- Editorial: Altered metabolic traits in gastro-intestinal tract cancers, volume II.
- Racial Disparities in Pancreatic Cancer: A Comprehensive Population-Based Analysis of Survival, Surgical Access, and Prognostic Factors.
- Impact of Skeletal Muscle-related Parameters on Survival in Patients with Advanced Pancreatic Cancer Treated with Gemcitabine plus Nab-paclitaxel as First-line Chemotherapy.